Literature DB >> 24631324

Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease.

Sevgi Sayın1, Raif Cakmur2, Görsev G Yener2, Erdem Yaka2, Burcu Uğurel3, Fatma Uzunel2.   

Abstract

Dyskinesias are one of the most frequent and disabling complications of the long-term treatment of Parkinson's disease (PD). Although the cause is not completely understood, it appears that an imbalance between excitatory and inhibitory inputs from the basal ganglia to the motor cortex leads to overactivation of motor and premotor areas. Overactivation of the supplementary motor area (SMA) has been observed in neuroimaging studies in dyskinetic PD patients. We investigated the effects of low-frequency repetitive transcranial magnetic stimulation (rTMS) of the SMA on levodopa-induced dyskinesias (LID) and motor performance in PD. We tested whether longer duration (10days) and higher number of total pulses (1800 pulses) would enhance the beneficial effect. Seventeen dyskinetic PD patients were randomly assigned to real rTMS or sham (placebo) rTMS, and 1Hz rTMS or sham rTMS was applied over the SMA for 10 consecutive days. Patients were assessed at baseline and 1day after the last rTMS with a levodopa challenge test, and video recordings were taken. Dyskinesias and motor performance were rated off-line by two blinded raters using video recordings. After 10days of treatment with rTMS, we observed that 1Hz rTMS delivered over the SMA had decreased LID lasting for 24hours without a change in motor performance, whereas sham rTMS induced no significant change in dyskinesia scores. These results support a possible therapeutic effect of low-frequency rTMS in LID. However, in order to suggest rTMS as an effective treatment, long-term observations and further investigations with a larger patient population are essential.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dyskinesia; Motor performance; Parkinson’s disease; Repetitive transcranial magnetic stimulation; Supplementary motor area

Mesh:

Substances:

Year:  2014        PMID: 24631324     DOI: 10.1016/j.jocn.2013.11.025

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  7 in total

Review 1.  Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence.

Authors:  Ritam Bandopadhyay; Nainshi Mishra; Ruhi Rana; Gagandeep Kaur; Mohammed M Ghoneim; Sultan Alshehri; Gulam Mustafa; Javed Ahmad; Nabil A Alhakamy; Awanish Mishra
Journal:  Front Pharmacol       Date:  2022-04-07       Impact factor: 5.988

Review 2.  Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 3.  Novel targeted therapies for Parkinson's disease.

Authors:  Theodora Ntetsika; Paraskevi-Evita Papathoma; Ioanna Markaki
Journal:  Mol Med       Date:  2021-02-25       Impact factor: 6.354

4.  The Supplementary Motor Complex in Parkinson's Disease.

Authors:  Shervin Rahimpour; Shashank Rajkumar; Mark Hallett
Journal:  J Mov Disord       Date:  2021-11-25

Review 5.  Therapeutic Devices for Motor Symptoms in Parkinson's Disease: Current Progress and a Systematic Review of Recent Randomized Controlled Trials.

Authors:  Joji Fujikawa; Ryoma Morigaki; Nobuaki Yamamoto; Teruo Oda; Hiroshi Nakanishi; Yuishin Izumi; Yasushi Takagi
Journal:  Front Aging Neurosci       Date:  2022-03-29       Impact factor: 5.702

6.  Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.

Authors:  Maowen Ba; Min Kong; Lina Guan; Maoli Yi; Hongli Zhang
Journal:  Oncotarget       Date:  2016-09-13

7.  Quantitative Electroencephalography Characteristics for Parkinson's Disease: A Systematic Review.

Authors:  Lívia Shirahige; Marina Berenguer-Rocha; Sarah Mendonça; Sérgio Rocha; Marcelo Cairrão Rodrigues; Kátia Monte-Silva
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.